Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
AEye Inc Q1 2026 Earnings Call - Revenue Surges 60% as Defense and Smart Infrastructure Traction Offsets Slow Auto Ramp
AEye Inc. delivered a Q1 2026 revenue jump of nearly 60% year-over-year, driven by a broadening commercial funnel and a strategic pivot toward end-to-end perception solutions. The company’s customer b...
- Q1 2026 revenue surged to $101,000, a nearly 60% year-over-year increase from $64,000 in Q1 2025, signaling early commercial traction.
- The active customer base grew from 16 to 21, with both issued quotes and active technical engagements rising by approximately 40% quarter-over-quarter.
- Defense is emerging as a high-velocity market, highlighted by a new commercial partnership with SynTech and repeat business from a major U.S. contractor for UAV applications.
- +7 more takeaways
Allogene Therapeutics Q1 2026 Earnings Call - ALPHA3 MRD Clearance Signals Shift Toward Outpatient CAR T Care
Allogene Therapeutics reported a pivotal interim futility analysis from its ALPHA3 trial, where cema-cel achieved a 58.3% minimal residual disease (MRD) clearance rate in first-line large B-cell lymph...
- ALPHA3 Interim Futility Analysis: cema-cel achieved 58.3% MRD clearance vs 16.7% in observation, a 41.6 percentage point absolute difference.
- Safety Profile Enables Outpatient Care: No CRS, ICANS, or treatment-related hospitalizations observed, supporting outpatient administration feasibility.
- ctDNA Reduction: Median ctDNA levels decreased by ~98% in cema-cel arm vs 26% increase in observation by day 45.
- +9 more takeaways
Eton Pharmaceuticals Q1 2026 Earnings Call - Raises Full-Year Revenue Guidance to $120M on Record Growth and HEMANGEOL Launch
Eton Pharmaceuticals delivered a record first quarter with $24.3 million in product sales, a 73% year-over-year increase, driven by strong performance across its rare disease portfolio and the recent ...
- Record Q1 2026 product sales of $24.3 million, up 73% year-over-year, driven by INCRELEX, ALKINDI, Galzin, and carglumic acid.
- Full-year revenue guidance raised to exceed $120 million, up from $110 million, reflecting strong outperformance and early HEMANGEOL/DESMODA traction.
- Adjusted EBITDA reached $5.7 million (24% margin); management maintains goal of >30% full-year margin and 50% by 2028.
- +9 more takeaways
MDxHealth Q1 2026 Earnings Call - Strategic Pivot to Prostate Cancer Diagnostics Amid Resolve UTI Exit
MDxHealth is executing a decisive pivot away from its Resolve UTI diagnostic line to concentrate exclusively on its core prostate cancer precision testing portfolio. The decision stems from mounting r...
- 1. MDxHealth is exiting its Resolve UTI diagnostic business and closing its Plano, Texas laboratory to eliminate reimbursement volatility and refocus exclusively on prostate cancer precision diagnostics.
- 2. Core prostate cancer revenue grew 11% year-over-year to $23.9 million on a pro forma basis, excluding the discontinued Resolve business, demonstrating continued commercial execution.
- 3. The company announced updated 2026 revenue guidance for its core cancer business of $110 million to $115 million, representing 20% to 26% year-over-year growth.
- +9 more takeaways
Innventure Q1 2026 Earnings Call - Two-Phase Cooling Bookings Surge Amid AI Infrastructure Buildout
Innventure reported Q1 2026 consolidated revenue of $1.4 million, up from $0.2 million in Q1 2025, driven by Accelsius’ $1.3 million in revenue, its highest quarterly total since 2024. The company sec...
- Consolidated Q1 2026 revenue reached $1.4 million, up from $0.2 million in Q1 2025, with Accelsius contributing $1.3 million, marking its highest quarterly revenue since 2024.
- Innventure secured $50 million in bookings during Q1 2026, reflecting early-stage customer validation and integration of its two-phase direct-to-chip liquid cooling technology.
- Management reaffirmed its target of achieving a $100 million annualized revenue run rate by year-end 2026, implying a monthly revenue run rate of $8–9 million, though full-year revenue is not forecasted.
- +7 more takeaways
WidePoint Corporation Q1 2026 Earnings Call - Momentum Builds as DHS Funding Clears Path for CWMS 3.0 Award
WidePoint reported a strong first quarter of 2026, with revenue jumping 21% to $40.6 million and adjusted EBITDA surging to $752,000. The company posted its first net income since 2021, driven by robu...
- Revenue surged 21% year-over-year to $40.6 million, driven by a $3.4 million increase in carrier services fees and normalization of reselling revenues.
- Adjusted EBITDA jumped to $752,000 from $92,000 in Q1 2025, with sequential growth of 64% over Q4 2025, signaling strong operational momentum.
- Free cash flow nearly doubled to $674,000, up from $65,000 in the prior year period, reflecting improved working capital and cash conversion.
- +7 more takeaways
Gambling.com Group Q1 2026 Earnings Call - Data Services Surge Offsets Marketing Decline Amid AI-Driven Restructuring
Gambling.com Group delivered flat Q1 revenue of EUR 40.4 million as a 13% jump in sports data services, fueled by OpticOdds enterprise growth and AI integrations with Claude and Perplexity, canceled o...
- 1. Q1 2026 revenue of EUR 40.4 million remained flat year-over-year, with data services up 13% to EUR 11.2 million offsetting a 5% decline in marketing revenue to EUR 29.2 million.
- 2. Sports data services now represent 28% of total revenue, the highest share ever, with enterprise and consumer segments contributing roughly equally for the first time.
- 3. OpticOdds drove data growth with 94% new deal growth year-over-year, including a 178% surge in international partners, and 86% of customers now using API-based solutions.
- +9 more takeaways
HeartFlow Q1 2026 Earnings Call - Plaque Adoption Accelerates, Full-Year Revenue Raised
HeartFlow delivered a strong first quarter of 2026, with revenue rising 41% year-over-year to $52.6 million and global case volume surging 67%. The standout catalyst was Plaque Analysis, which generat...
- Revenue of $52.6 million in Q1 2026, up 41% year-over-year, driven by 67% global case growth.
- Plaque Analysis revenue reached $3.2 million in Q1, with full-year guidance raised to $19–$21 million.
- Full-year revenue guidance increased to $228–$232 million, representing 29–32% year-over-year growth.
- +7 more takeaways
Genasys Inc. Q2 2026 Earnings Call - Profitability Achieved as Puerto Rico Receivables Drive Debt Extension
Genasys Inc. reported a pivotal second quarter for fiscal 2026, delivering its first GAAP net income profitability alongside a 124% year-over-year revenue surge to $15.5 million. The quarter was defin...
- Genasys achieved its first GAAP net income profitability in Q2 2026, reporting $600,000 in net income compared to a $6.1 million loss in the prior year period.
- Total revenue surged 124% year-over-year to $15.5 million, with hardware revenue driving the majority of the growth at an approximate 180% increase.
- The Puerto Rico Dam Emergency Warning System project contributed $10.3 million to Q2 revenue, underscoring the critical role of this multi-year contract in current financial performance.
- +7 more takeaways
Newton Golf Company Q1 2026 Earnings Call - Record 2025 Growth Paused by Factory Overhaul, OEM Talks Heat Up
Newton Golf reported an 18% drop in Q1 2026 revenue to $1 million, a deliberate stumble caused by a factory overhaul designed to scale production and improve product quality. Management treated Q1 as ...
- Q1 2026 revenue fell 18% to $1 million, a deliberate dip driven by temporary manufacturing constraints and delayed order fulfillment as the company overhauled its production processes.
- Gross margin contracted to 63% from 70% in the prior year quarter, reflecting lower production volumes that reduced fixed cost absorption and manufacturing utilization.
- Operating expenses rose 15% to $3.2 million, fueled by $0.2 million in bonus accruals and higher labor costs tied to temporary production inefficiencies and R&D scaling initiatives.
- +7 more takeaways